GlassScriptPhysician profile
Thomas W Martin
NPI 1558551127
$11,193.85
in general payments reported to CMS, 2019-2025
46 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $834 · 2021: $1,194 · 2022: $1,207 · 2023: $1,560 · 2024: $3,317 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734 · Travel and Lodging: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.20 |
| Travel and Lodging | $2,002.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,619.25 | 2019-2025 | Superion Indirect Decompression System, Spectra Wavewriter, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $2,353.10 | 2019-2025 | Proclaim |
| Spinal Simplicity, LLC | $1,609.36 | 2023-2025 | Ha Minuteman G3-R |
| Si-Bone, INC. | $612.28 | 2023 | |
| Abbvie INC. | $401.66 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.02 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $322.91 | 2019-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $320.27 | 2019-2025 | Ztlido |
| Amgen INC. | $218.49 | 2019-2025 | Krystexxa |
| Almatica Pharma LLC | $200.04 | 2021-2023 | Gralise |
| Nevro Corp. | $180.14 | 2019-2024 | Senza |
| Forte Bio-Pharma LLC | $173.91 | 2020 | |
| Saluda Medical Americas, INC. | $165.30 | 2023 | Evoke Scs |
| Biodelivery Sciences International, INC. | $160.76 | 2020-2021 | |
| Sentynl Therapeutics, INC. | $127.12 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.